The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Revised Response Criteria for Malignant Lymphoma

Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,452

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Hallek, M. J., Cheson, B. D., Catovsky, D., Caligaris‐Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,782

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686

International uniform response criteria for multiple myeloma

Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445

Multiple Myeloma

Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382

Multiple myeloma

Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137

Initial genome sequencing and analysis of multiple myeloma

Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,457

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Siegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 664

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Simon, R. M., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 641

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Yap, T. A., Li, Y., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K. P., Baird, R. D., Delgado, L., Taylor, A. B., Lupinacci, L. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 540

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381

Clinical Course of Patients With Relapsed Multiple Myeloma

Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365

Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs

Markman, B., Dienstmann, R., & Tabernero, J. M. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 357

Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia

Crouthamel, M., Kahana, J. A., Korenchuk, S., Zhang, S., Sundaresan, G., Eberwein, D. J., Brown, K. K., & Kumar, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1253 · Cited by 134

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

McMillin, D. W., Ooi, M. G. M., Delmore, J. E., Negri, J. M., Hayden, P. J., Mitsiades, N., Jakubı́ková, J., Maira, S.-M., Garcı́a-Echeverrı́a, C., Schlossman, R. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4285 · Cited by 124

Darwinian evolution and tiding clones in multiple myeloma

Bahlis, N. J. (2012) · Blood · doi:10.1182/blood-2012-06-430645 · Cited by 82

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma

Mitsiades, C. S., Davies, F. E., Laubach, J. P., Joshua, D., Miguel, J. F. S., Anderson, K. C., & Richardson, P. G. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0760 · Cited by 82

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M., & Bargou, R. C. (2010) · Blood · doi:10.1182/blood-2010-05-284422 · Cited by 82

An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo

Cherrin, C., Haskell, K., Howell, B., Jones, R., Leander, K. R., Robinson, R., Watkins, A., Bilodeau, M. T., HOFFMAN, J. M. J., Sanderson, P. E. J., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11100 · Cited by 61

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.

Burris, H. A., Siu, L. L., Infante, J. R., Wheler, J. J., Kurkjian, C. D., Opalinska, J., Smith, D. A., Antal, J. M., Gauvin, J., Gonzalez, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3003 · Cited by 50

Combined targeting of MEK/MAPK and PI 3 K/Akt signalling in multiple myeloma

Steinbrunn, T., Stühmer, T., Sayehli, C., Chatterjee, M., Einsele, H., & Bargou, R. C. (2012) · British Journal of Haematology · doi:10.1111/bjh.12039 · Cited by 49

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

Jain, S. S., Diefenbach, C., Zain, J. M., & O’Connor (2011) · Core evidence · doi:10.2147/ce.s13838 · Cited by 47

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma

Munugalavadla, V., Mariathasan, S., Slaga, D., Du, C., Berry, L., Rosario, G. D., Yan, Y., Boe, M., Sun, L., Friedman, L. S., et al. (2013) · Oncogene · doi:10.1038/onc.2012.594 · Cited by 41

Novel therapeutics in multiple myeloma

Stewart, A. K. (2012) · Hematology · doi:10.1179/102453312x13336169156131 · Cited by 21

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813

Proteasome inhibitors in cancer therapy

Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 577

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 473

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)

Nițulescu, G. M., Margina, D. M., Juzenas, P., Peng, Q., Olaru, O. T., Saloustros, E. S., Fenga, C., Spandidos, D. A., Libra, M., & Tsatsakis, A. M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 382

Afuresertib Shows Activity Against Multiple Myeloma

Lawrence, L. (2014)

A key to the quest?

Leleu, X. P. (2014) · Blood · doi:10.1182/blood-2014-08-593822 · Cited by 1

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

Garcia‐Manero, G., Tibes, R., Kadia, T. M., Kantarjian, H. M., Arellano, M. L., Knight, E., Xiong, H., Qin, Q., Munasinghe, W. P., Roberts-Rapp, L. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0242-6 · Cited by 21

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158

Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

Spencer, A. G., Yoon, S., Harrison, S. J., Morris, S. R., Smith, D. A., Freedman, S. J., Brigandi, R. A., Oliff, A. I., Opalinska, J., & Chen, C. I. (2011) · Blood · doi:10.1182/blood.v118.21.1856.1856 · Cited by 16